The UK and US have concluded a major bilateral deal that will ensure no duties on British drug shipments going into the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase funding on drugs through the public health system. This commitment ensures that import taxes on these vital exports will stay at nothing for a timeframe of 36 months.
This development follows previous warnings to significantly raise duties on patented pharmaceutical products, with figures mentioned reaching 100%.
"This agreement with the UK strengthens the worldwide climate for cutting-edge drugs and brings much-needed balance to American-British drug exports," an announcement said.
Trade Importance
Drugs represent one of the UK's largest export categories to the America, which is clearly the biggest buyer for large British pharmaceutical firms.
Export figures show that in the one-year period to the end of last September, the UK sold drugs worth £11.1bn to the US. This figure made up a significant portion of British export trade in that period.
"This guarantee protects jobs, boosts funding and sets the stage for the UK to establish itself as a global hub for life sciences," a government official commented.
Key UK Commitments
The pact entails several specific changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall public funding on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded twenty percent.
Recent Tensions
This agreement comes amid a protracted tension between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were intensified by assertions that American customers were paying several times more for the same drugs than people in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a share of its resources over the past decade.